Cardiol Therapeutics Inc. CRDL
1.01 USD -0.01 (-0.98%)
At closeNov 11, 2026, 4:00 PM EST
1.02 +0.01 +0.99%
After hours · Nov 11, 4:00 PM ET
1.01 Day range 1.07
0.88 52-week range 2.34
- YTD
- +5.87%
- 1 year
- -2.88%
News
prnewswire.com Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC TORONTO, Nov. 3, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and…
benzinga.com HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
benzinga.com Cardiol Therapeutics Announces Enrollment Progress And Plans To Expand Its MAVERIC Phase III Trial Evaluating CardiolRx For Risk Reduction Of Recurrence In Patients With Recurrent Pericarditis As of September 23, 2026, 110 patients have been enrolled in MAVERIC, achieving the Company's original recruitment target ahead of its end-of-September guidance."A blinded review of events in MAVERIC…
prnewswire.com Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy Original 110-patient enrollment target achieved ahead of the Company's end-of-September guidance. The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to capture…
prnewswire.com Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in recurrent pericarditis and extends cash runway into H1 2028. TORONTO, Sept.
zacks.com 5 Small Drug Stocks Poised to Benefit From a Biotech Recovery INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
benzinga.com Cardiol Therapeutics Files $150M Base Shelf Prospectus, Enabling Future Offerings Of Shares, Debt, Warrants And Other Securities Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today
prnewswire.com Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission TORONTO, Sept. 10, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and…
prnewswire.com Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference TORONTO, Sept. 9, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion. SCYNEXIS (NASDAQ:SCYX) stock…
zacks.com Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year? Here is how Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
zacks.com Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy? Does Cardiol Therapeutics Inc. (CRDL) have what it takes to be a top stock pick for momentum investors? Let's find out.
benzinga.com Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $10 Canaccord Genuity analyst Edward Nash maintains Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and raises the price target from $8 to $10.
marketbeat.com Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial Cardiol Therapeutics NASDAQ: CRDL is advancing its synthetic, pharmaceutical-grade cannabidiol formulation, CardiolRx, in a pivotal Phase III trial for recurrent pericarditis, with management…
defenseworld.net Cardiol Therapeutics (CRDL) Expected to Post Earnings on Thursday Cardiol Therapeutics (NASDAQ: CRDL - Get Free Report) is expected to post its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to announce earnings of…
prnewswire.com Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference TORONTO, Aug. 5, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and…- benzinga.com HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
benzinga.com Cardiol Therapeutics Announces Publication Of Phase II MAvERIC Study Results In The Journal of the American Heart Association The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment. The publication describes clinical findings in which CardiolRx™ was associated with rapid and sustained…
prnewswire.com Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association • Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion. TORONTO, July 14, 2026 /PRNewswire/ -- Cardiol Therapeutics…
prnewswire.com Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit TORONTO, July 9, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and…
prnewswire.com Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and…
prnewswire.com Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT TORONTO, June 23, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
prnewswire.com Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ TORONTO, May 14, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and…
prnewswire.com Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recurrent pericarditis and further validate the ongoing Phase III trial, which recently surpassed 75%…
prnewswire.com Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwestern University, Massachusetts General Hospital, Columbia University–NewYork-Presbyterian, NYU…
defenseworld.net Contrasting Corcept Therapeutics (NASDAQ:CORT) & Cardiol Therapeutics (NASDAQ:CRDL) Corcept Therapeutics (NASDAQ: CORT - Get Free Report) and Cardiol Therapeutics (NASDAQ: CRDL - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two…
newsfilecorp.com Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the…- benzinga.com Cardiol Advances Key Studies and Secures Funding to Push New Heart Treatments Forward Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
benzinga.com Cardiol Therapeutics Announces Publication Of Results From Phase II ARCHER Study In ESC Heart Failure, Journal Of European Society Of Cardiology Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic…
benzinga.com Cardiol Therapeutics Surpasses 50% Participant Enrollment In MAVERIC Phase III Study Of CardiolRx Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic…
benzinga.com Why MongoDB Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket - benzinga.com HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
benzinga.com Cardiol Therapeutics Announces New, Comprehensive Data From ARCHER, Randomized Double-Blind, Placebo-Controlled, Multi-Center Phase II Clinical Trial Of CardiolRx In Patients With Acute Myocarditis Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with…- benzinga.com Cardiol Therapeutics Q3 EPS $(0.09), Inline Cardiol Therapeutics (NASDAQ:CRDL) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 30.77 percent increase over losses of $(0.13) per share from the…
- benzinga.com Cardiol Therapeutics Receives USPTO Notice Of Allowance For Patent On Cannabidiol Heart Therapies Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual…
- benzinga.com Cardiol Therapeutics To Present New Data From ARCHER Trial, Highlighting Magnitude Of Reduction In LV Mass And Read Through To Heart Failure, At Cardiology Conference In November MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the…
- benzinga.com Cardiol Therapeutics Completes $11M Private Placement Selling 11M Units At $1/Unit; Says MAVERIC Phase III Pivotal Trial Of Orphan Drug Candidate CardiolRx In Recurrent Pericarditis Is Fully Funded Through To A Planned NDA Submission With The FDA; Data From The ARCHER Trial To Be Presented At A Cardiology Conference In November 2025 MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the…
- benzinga.com Cardiol Therapeutics Reports Compelling ARCHER Trial Results Supporting Advancement of CardiolRx And CRD-38 in Myocarditis And Heart Failure Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx™ over placebo.Reduction in ECV was associated with…
- benzinga.com Cardiol Locks Key Trial Data as It Advances New Treatment for Dangerous Heart Inflammation Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the…
benzinga.com This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - benzinga.com HC Wainwright & Co. Initiates Coverage On Cardiol Therapeutics with Buy Rating, Announces Price Target of $9 HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Cardiol Therapeutics (NASDAQ:CRDL) with a Buy rating and announces Price Target of $9.
- benzinga.com HC Wainwright & Co. Initiates Coverage On Cardiol Therapeutics with Buy Rating, Announces Price Target of $9 HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Cardiol Therapeutics (NASDAQ:CRDL) with a Buy rating and announces Price Target of $9.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
- benzinga.com Cardiol Therapeutics Enrolls First Patient In Pivotal Phase III MAVERIC Trial Evaluating CardiolRx For Prevention Of Recurrent Pericarditis Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.Based on a successful…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
benzinga.com HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday morning, 446 companies hit new 52-week lows.